
Senators push back against Vought's call for more partisan spending process
Office of Management and Budget Director Russ Vought told reporters during a Christian Science Monitor Breakfast Thursday morning that he believed "the appropriations process has to be less bipartisan."
His sentiment came on the heels of Senate Republicans advancing President Donald Trump's $9 billion clawback package, which would cancel congressionally approved funding for foreign aid and public broadcasting, just a few hours before.
Unlike the hyper-partisan bills that have dominated the Senate's recent agenda, including the rescissions package and the president's "big, beautiful bill," the appropriations process is typically a bipartisan affair in the upper chamber.
That is because, normally, most bills brought to the floor have to pass the Senate's 60-vote threshold, and with the GOP's narrow majority, Senate Democrats will need to pass any spending bills or government funding extensions to ward off a partial government shutdown.
Senate Majority Leader Chuck Schumer, D-N.Y., who alluded to issues down the line with the appropriations process if Republicans advanced Trump's resicssions package, took a harsh stance against Vought.
"Donald Trump should fire Russell Vought immediately, before he destroys our democracy and runs the country into the ground," Schumer said.
Members of the Senate Appropriations Committee also did not take kindly to Vought's comments.
"I think he disrespects it," Sen. Lisa Murkowski, R-Alaska, said. "I think he thinks that we are irrelevant, and I wish I had actually heard the speech, because, you know, again, everything in context."
"But you have to admit that when you look at the quotes that are highlighted in the story this morning, it is pretty dismissive of the appropriations process, pretty dismissive," she continued.
Vought has no intention of slowing the rescissions train coming from the White House, and said that there would be more rescissions packages on the way.
He noted another would "come soon," as lawmakers in the House close in on a vote to send the first clawback package to the president's desk.
"There is no voter in the country that went to the polls and said, 'I'm voting for a bipartisan appropriations process,'" Vought said. "That may be the view of something that appropriators want to maintain."
Both Murkowski and Senate Appropriations Chair Susan Collins, R-Maine, voted against the rescissions package, and warned of the cuts to public broadcasting, lack of transparency from the OMB and the possible effect it could have on legislating in the upper chamber.
"I disagree with both those statements," Collins said of Vought's push for a more partisan appropriations process. "Just as with the budget that the President submitted, we had to repeatedly ask him and the agencies to provide us with the detailed account information, which amounts to 1000s of pages that our appropriators and their staff meticulously review."
Fox News Digital reached out to the OMB for comment.
Vought's comments came at roughly the same time as appropriators were holding a mark-up hearing of the military construction and veterans' affairs and Commerce, Justice and Science spending bills.
Sen. Patty Murray, the top Democrat on the Senate Appropriations Committee, said during the hearing that Senate Republicans coalescing behind the rescissions package would only make hammering out spending bills more difficult, and argued that "trust" was at the core of the process.
"That's part of why bipartisan bills are so important," she said. "But everyone has to understand getting to the finish line always depends on our ability to work together in a bipartisan way, and it also depends on trust."
Other Republicans on the panel emphasized a similar point, that, without some kind of cooperation, advancing spending bills would become even more challenging.
Sen. John Hoeven, R-N.D., said that finding "critical mass" to move spending bills was important, and warned that people have to "quit saying it's gotta just be my way or the highway," following threats Schumer's threats last week that the appropriations process could suffer should the rescissions package pass.
"People better start recognizing that we're all gonna have to work together and hopefully get these [appropriations] bills to the floor and see what we can move," he said. "But if somebody just sits up and says, 'Oh, because there's a rescission bill, then I'm not going to work on Appropriations,' you can always find an excuse not to do something. Let's figure out how we can work forward."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating
Spotify Technology S.A. (NYSE:SPOT) is among the 13 Best Global Stocks to Buy Right Now. On July 11, Keybanc lifted the stock's price target to $860 from $640, while maintaining an Overweight rating for its shares. The adjustment represents significant upside potential, given its share price of $674.46 at the close on July 23. Copyright: dennizn / 123RF Stock Photo The firm said that it expects Spotify Technology S.A. (NYSE:SPOT)'s second-quarter results and guidance for the third quarter to contain some variability related to foreign exchange, seasonal gross margin dynamics, and social charges. The analyst has advised investors to buy any near-term dips and reiterated that its core thesis remains intact. Keybanc believes that music is under-monetized in a price inflationary market with favorable competitive dynamics and several initiatives that support high-teens revenue growth. In other news, Deutsche Bank on Wednesday also raised Spotify Technology S.A. (NYSE:SPOT)'s target price to $775 from $700 and maintained a Buy rating for its shares. The Luxembourg-based company, which provides digital music-streaming services worldwide, has seen impressive returns in 2025, gaining 51% year-to-date. While we acknowledge the potential of SPOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds and 13 Best Booming Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.